57
Views
12
CrossRef citations to date
0
Altmetric
Antimicrobial Chemotherapy

Three-Times Weekly Teicoplanin as Outpatient Treatment of Chronic Osteoarticular Infections

Pages 421-425 | Published online: 18 Jul 2013
 

Abstract

Treatment of difficult-to-treat infections such as osteomyelitis or infections related to indwelling medical devices requires lengthy antibiotic therapy and adequate surgical debridement. teicoplanin, a glycopeptide antibiotic with a long half-life, was used three-times weekly in the treatment of these infections. After a period of daily dosing with teicoplanin, patients were treated with an intravenous dose of 12 mg on mondays, Wednesdays and Fridays. A control group of patients were treated with teicoplanin daily. Teicoplanin levels were measured during the study. Thirty-six patients were enrolled in the study: 14 with vertebral osteomyelitis, 12 with infected orthopedic implants, 7 with osteomyelitis and 3 with arterial prosthetic infections. The duration of treatment ranged from 60 to 360 days. Cure was obtained in 21 (58%) patients and improvement in 15 (42%) patients. trough and peak serum concentrations in three-time weekly patients were 16.2±7.2 mg/L and 58.7±14.4 mg/L. in the control group trough and peak serum concentrations were 18.9±13.6 mg/L and 52.2±27 mg/L. Adverse events occurred in 6 patients: mainly mild liver toxicity. three times weekly teicoplanin seems to be a valuable option in the treatment of chronic infections.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.